eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
13.01
+0.50 (4.00%)
May 9, 2025, 4:00 PM - Market closed
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
31
Market Cap
108.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEXOZ News
- 2 days ago - eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST - Accesswire
- 3 days ago - eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health - Accesswire
- 18 days ago - Bringing clarity and precision to the cell-free space by introducing exozymes - GlobeNewsWire
- 4 weeks ago - BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - GlobeNewsWire
- 5 weeks ago - eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewsWire
- 5 weeks ago - eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewsWire
- 6 weeks ago - eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewsWire
- 2 months ago - eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - GlobeNewsWire